0 838

Cited 5 times in

Clinical impact of early recovery of peripheral blood absolute lymphocyte count after frontline autologous stem cell transplantation for diffuse large B-cell lymphoma

DC Field Value Language
dc.contributor.author김수정-
dc.contributor.author김윤덕-
dc.contributor.author김진석-
dc.contributor.author민유홍-
dc.contributor.author이정연-
dc.contributor.author장지은-
dc.contributor.author정준원-
dc.contributor.author정해림-
dc.contributor.author조현수-
dc.date.accessioned2018-07-20T11:58:14Z-
dc.date.available2018-07-20T11:58:14Z-
dc.date.issued2017-
dc.identifier.issn0278-0232-
dc.identifier.urihttps://ir.ymlib.yonsei.ac.kr/handle/22282913/161564-
dc.description.abstractWe conducted a retrospective study to evaluate the clinical impact of an early recovery of posttransplant absolute lymphocyte count (ALC) on the outcome of frontline autologous stem cell transplantation (ASCT) for diffuse large B-cell lymphoma (DLBCL). We reviewed 65 DLBCL patients who underwent frontline ASCT after primary chemotherapy based on cyclophosphamide, doxorubicin, vincristine, and prednisone. A receiver operating characteristic analysis was performed to determine the optimal cut point (0.4 × 109 /L) for an ALC at 15 days after ASCT (ALC-15). Both event-free survival and overall survival rates of the higher-ALC-15 group were significantly better than those of the lower-ALC-15 group (event-free survival, P = .008; overall survival, P = .013). The infused CD34+ cell count was significantly associated with the recovery of ALC-15 (>0.4 × 109 /L) after ASCT (P = .028). A multivariate analysis confirmed that a higher infused CD34+ cell dose (>5.0 × 106 cells/kg) was an independent factor affecting an early recovery of ALC after ASCT (odds ratio, 4.145; 95% confidence interval, 1.106-15.528; P = .035). In conclusion, an early recovery of ALC after ASCT can be regarded as a good prognostic marker in patients with DLBCL who have undergone frontline ASCT. We found that the infused CD34+ cell dose for ASCT was associated with the recovery of ALC.-
dc.description.statementOfResponsibilityrestriction-
dc.languageEngland-
dc.relation.isPartOfHEMATOLOGICAL ONCOLOGY-
dc.rightsCC BY-NC-ND 2.0 KR-
dc.rightshttps://creativecommons.org/licenses/by-nc-nd/2.0/kr/-
dc.subject.MESHAdult-
dc.subject.MESHAged-
dc.subject.MESHDisease-Free Survival-
dc.subject.MESHFemale-
dc.subject.MESHHematopoietic Stem Cell Transplantation/methods*-
dc.subject.MESHHumans-
dc.subject.MESHLymphocyte Count/methods*-
dc.subject.MESHLymphoma, Large B-Cell, Diffuse/drug therapy*-
dc.subject.MESHMale-
dc.subject.MESHMiddle Aged-
dc.subject.MESHPrognosis-
dc.subject.MESHRetrospective Studies-
dc.subject.MESHTransplantation Conditioning/methods*-
dc.subject.MESHTransplantation, Autologous/methods*-
dc.subject.MESHYoung Adult-
dc.titleClinical impact of early recovery of peripheral blood absolute lymphocyte count after frontline autologous stem cell transplantation for diffuse large B-cell lymphoma-
dc.typeArticle-
dc.contributor.collegeCollege of Medicine-
dc.contributor.departmentDept. of Internal Medicine-
dc.contributor.googleauthorYundeok Kim-
dc.contributor.googleauthorSoo‐Jeong Kim-
dc.contributor.googleauthorJune‐Won Cheong-
dc.contributor.googleauthorHyunsoo Cho-
dc.contributor.googleauthorHaerim Chung-
dc.contributor.googleauthorJung Yeon Lee-
dc.contributor.googleauthorJi Eun Jang-
dc.contributor.googleauthorYoo Hong Min-
dc.contributor.googleauthorJin Seok Kim-
dc.identifier.doi10.1002/hon.2332-
dc.contributor.localIdA00633-
dc.contributor.localIdA00790-
dc.contributor.localIdA01017-
dc.contributor.localIdA01407-
dc.contributor.localIdA03114-
dc.contributor.localIdA03477-
dc.contributor.localIdA03729-
dc.contributor.localIdA04674-
dc.relation.journalcodeJ03343-
dc.identifier.pmid27440113-
dc.identifier.urlhttps://onlinelibrary.wiley.com/doi/abs/10.1002/hon.2332-
dc.subject.keywordabsolute lymphocyte count-
dc.subject.keyworddiffuse large B-cell lymphoma-
dc.subject.keywordfrontline autologous stem cell transplantation-
dc.subject.keywordprognostic marker-
dc.contributor.alternativeNameKim, Soo Jeong-
dc.contributor.alternativeNameKim, Yun Deok-
dc.contributor.alternativeNameKim, Jin Seok-
dc.contributor.alternativeNameMin, Yoo Hong-
dc.contributor.alternativeNameLee, Jung Yoen-
dc.contributor.alternativeNameJang, Ji Eun-
dc.contributor.alternativeNameCheong, June Won-
dc.contributor.alternativeNameChung, Hae Rim-
dc.contributor.affiliatedAuthorKim, Soo Jeong-
dc.contributor.affiliatedAuthorKim, Yun Deok-
dc.contributor.affiliatedAuthorKim, Jin Seok-
dc.contributor.affiliatedAuthorMin, Yoo Hong-
dc.contributor.affiliatedAuthorLee, Jung Yoen-
dc.contributor.affiliatedAuthorJang, Ji Eun-
dc.contributor.affiliatedAuthorCheong, June-Won-
dc.contributor.affiliatedAuthorChung, Hae Rim-
dc.citation.volume35-
dc.citation.number4-
dc.citation.startPage465-
dc.citation.endPage471-
dc.identifier.bibliographicCitationHEMATOLOGICAL ONCOLOGY, Vol.35(4) : 465-471, 2017-
dc.identifier.rimsid61593-
dc.type.rimsART-
Appears in Collections:
1. College of Medicine (의과대학) > Dept. of Internal Medicine (내과학교실) > 1. Journal Papers

qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.